Cumulative incidence of CMV reactivation and gastroenteritis. The cumulative incidence of CMV reactivation (A), the adjusted cumulative incidence of CMV reactivation in patients with and without letermovir prophylaxis (B), the cumulative incidence of CMV gastroenteritis (C), and the adjusted cumulative incidence of CMV gastroenteritis in patients with and without letermovir prophylaxis (D). Adjusted curves were plotted with the following covariates: recipient’s age at HCT, sex mismatch, CMV serological status, disease, DRI, KPS, HCT-CI, donor source, conditioning intensity, GVHD prophylaxis, in vivo T-cell depletion, year of HCT, organ involvement sites of aGVHD, and use of systemic steroids.